Jiangsu Vcare Approved to Establish "Nanjing Key Laboratory for Artificial Intelligence (AI) Drug Design"

Recently, following joint review by Nanjing Jiangbei New Area Sci-Tech Bureau and Nanjing Municipal Science and Technology Bureau, the"Nanjing Key Laboratory for Artificial Intelligence (AI) Drug Design"established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was approved as a 2025 Nanjing Key Laboratory. This marks authoritative recognition of Jiangsu Vcare’s scientific capabilities, with the Lab having achieved significant progress in drug design and molecular discovery.

Jiangsu Vcare specializes in innovative drugs and advanced therapies, recently emphasizing AI-enabled drug R&D. It formed a high-level AI drug design team, equipping the Lab with capabilities from molecular generation to screening and property prediction. Current AI models/algorithms have identified hit compounds in cardiovascular, autoimmune, solid tumors, and pulmonary fibrosis, now undergoing experimental validation.

Leveraging this platform, Jiangsu Vcare will explore new research fields, attract talent and resources, and enhance drug innovation capabilities to advance AI-enabled biopharmaceutical development.